On 19 August 2024, AbbVie announced that the European Commission (EC) has granted conditional marketing authorisation for its Tepkinly® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.
The EC first approved Tepkinly® in September 2023 as monotherapy for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Tepkinly® was co-developed by AbbVie and Genmab, and the companies share commercial responsibilities in the US and Japan.